ClinicalTrials.gov
public full text
Public Domain
Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation
Treatment of smokers with a tricyclic antidepressant, nortriptyline, can reduce tobacco withdrawal symptoms and increases long term cessation rates when combined with transdermal nicotine and a behavioral cessation programs. The study is a placebo-controlled, randomized, parallel group trial in which smokers aged 18-70 will be subject to the combination of oral and patch treatments.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Nicotine Patch Trial in Syrian Primary Care Settings#912512
- Pharmacologic Relapse Prevention for Alcoholic Smokers#1171967
- QuitAid Pilot Feasibility Trial#872987
- Efficacy and Safety of Rimonabant as an Aid to Smoking Cessation With or Without Nicotine Patch#886013
- Comparing Smoking Treatment Programs for Lighter Smokers - 1#857995
Record · ID 833583
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive